{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:49:57Z","timestamp":1767192597392,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: MDG1011 is an autologous TCR-T therapy developed as a treatment option for patients with myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and multiple myeloma (MM). It is specific for the target antigen PReferentially expressed Antigen in MElanoma (PRAME). The recombinant TCR used in MDG1011 recognizes PRAME100\u2013108 VLD-peptide presented by HLA-A*02:01-encoded surface molecules. Methods: Two preclinical batches of MDG1011, produced from enriched CD8+ T cells of healthy donors, underwent rigorous evaluation of on-target and off-target recognition of tumor cells and test cells representing healthy tissues. MDG1011 investigational medicinal products (IMPs) were produced for 13 patients. VLD-TCR surface expression was assessed using dual-marker flow cytometry using TCR V-beta-specific antibody and VLD\/HLA-A2-specific multimer. Functionality was assessed by interferon-gamma (IFN-\u03b3) secretion and cell-mediated cytotoxicity of target cells. Results: Preclinical MDG1011 batches displayed strong VLD-TCR expression, cytokine secretion, and cytotoxicity after antigen-specific activation, while showing no signals of on-target\/off-tumor or off-target recognition. All IMPs had good VLD-TCR expression as well as functionality after activation by multiple target cells. Conclusions: Preclinical studies demonstrated that MDG1011 displayed key 3S attributes of high specificity, sensitivity, and safety required for regulatory approval of a first-in-human (FIH) clinical study of patients with myeloid malignancies (CD-TCR-001: ClinicalTrials.gov Identifier: NCT03503968). MDG1011 IMP manufacturing was successful at 92%, even including heavily pretreated elderly patients with very advanced disease. The IMPs applied in nine patients all displayed antigen-specific functionality. Elsewhere, clinical study results for MDG1011 showed no dose-limiting toxicity and signs of biological and\/or clinical activity in several patients.<\/jats:p>","DOI":"10.3390\/cancers17020242","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:49:17Z","timestamp":1736761757000},"page":"242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of a 3S PRAME VLD-Specific T Cell Receptor and Its Use in Investigational Medicinal Products for TCR-T Therapy of Patients with Myeloid Malignancies"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2122","authenticated-orcid":false,"given":"Maja","family":"B\u00fcrdek","sequence":"first","affiliation":[{"name":"Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra U.","family":"Prinz","sequence":"additional","affiliation":[{"name":"Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5577-4500","authenticated-orcid":false,"given":"Kathrin","family":"Mutze","sequence":"additional","affiliation":[{"name":"Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Tippmer","sequence":"additional","affiliation":[{"name":"Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Geiger","sequence":"additional","affiliation":[{"name":"Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Longinotti","sequence":"additional","affiliation":[{"name":"Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores J.","family":"Schendel","sequence":"additional","affiliation":[{"name":"Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany"},{"name":"Medigene AG, 82152 Planegg-Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-Term Outcomes Following CAR T Cell Therapy: What We Know so Far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients with Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"doi-asserted-by":"crossref","unstructured":"Amor\u00f3s-P\u00e9rez, B., Rivas-Pardo, B., G\u00f3mez del Moral, M., Subiza, J.L., and Mart\u00ednez-Naves, E. (2024). State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?. Cells, 13.","key":"ref_8","DOI":"10.3390\/cells13090725"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and Challenges in CAR T Cell Therapy in Autoimmune Diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PPO.0000000000000378","article-title":"T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies","volume":"25","author":"Biernacki","year":"2019","journal-title":"Cancer J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-Engineered T Cell Therapy in Solid Tumors: State of the Art and Perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma (SPEARHEAD-1): An International, Open-Label, Phase 2 Trial","volume":"403","author":"Araujo","year":"2024","journal-title":"Lancet"},{"unstructured":"FDA (2024, October 15). FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma.","key":"ref_13"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbmt.2007.10.022","article-title":"T Cell Therapy in Allogeneic Stem Cell Transplantation","volume":"14","author":"Falkenburg","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"doi-asserted-by":"crossref","unstructured":"Yang, J., Chen, M., Ye, J., and Ma, H. (2024). Targeting PRAME for Acute Myeloid Leukemia Therapy. Front. Immunol., 15.","key":"ref_15","DOI":"10.3389\/fimmu.2024.1378277"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","article-title":"A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer","volume":"66","author":"Epping","year":"2006","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME Expression in Melanocytic Tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","article-title":"Safety and Immunogenicity of the Prame Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study","volume":"11","author":"Pujol","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME Is a Potential Immunotherapy Target in Sarcoma Subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin. Sarcoma Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin. Cancer Res."},{"doi-asserted-by":"crossref","unstructured":"Sailer, N., Fetzer, I., Salvermoser, M., Braun, M., Brechtefeld, D., Krendl, C., Geiger, C., Mutze, K., Noessner, E., and Schendel, D. (2022). T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. Cancers, 14.","key":"ref_21","DOI":"10.3390\/cancers14081998"},{"doi-asserted-by":"crossref","unstructured":"Schendel, D.J. (2023). Evolution by Innovation as a Driving Force to Improve TCR-T Therapies. Front. Oncol., 13.","key":"ref_22","DOI":"10.3389\/fonc.2023.1216829"},{"unstructured":"Medigene (2024, October 15). Medigene Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I\/II MDG1011 Trial in Blood Cancers, Available online: https:\/\/medigene.com\/medigene-reports-preliminary-efficacy-and-immune-monitoring-data-of-phase-i-of-phase-i-ii-mdg1011-trial-in-blood-cancers-1\/.","key":"ref_23"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2009-03-209387","article-title":"Dendritic Cells Pulsed with RNA Encoding Allogeneic MHC and Antigen Induce T Cells with Superior Anti-Tumor Activity and Higher TCR Functional Avidity","volume":"114","author":"Wilde","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e002035","DOI":"10.1136\/jitc-2020-002035","article-title":"Development of a CD8 Co-Receptor Independent T-Cell Receptor Specific for Tumor-Associated Antigen MAGE-A4 for next Generation T-Cell-Based Immunotherapy","volume":"9","author":"Davari","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00109-008-0317-3","article-title":"Enhanced Functionality of T Cell Receptor-Redirected T Cells Is Defined by the Transgene Cassette","volume":"86","author":"Leisegang","year":"2008","journal-title":"J. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/eji.1830271209","article-title":"Pro-Inflammatory Cytokines and Prostaglandins Induce Maturation of Potent Immunostimulatory Dendritic Cells under Fetal Calf Serum-Free Conditions","volume":"27","author":"Jonuleit","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/bioinformatics\/btv068","article-title":"Expitope: A Web Server for Epitope Expression","volume":"31","author":"Haase","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1682381","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical Evaluation of an Affinity-Enhanced MAGE-A4-Specific T-Cell Receptor for Adoptive T-Cell Therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1084\/jem.185.10.1859","article-title":"Complexes after Antigenic Stimulation","volume":"185","author":"Valitutti","year":"1997","journal-title":"J. Exp. Med"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4049\/jimmunol.1001775","article-title":"A TCR Targeting the HLA-A*0201\u2013Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer","volume":"186","author":"Chinnasamy","year":"2011","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-Derived HLA-A1\u2013Presented Peptide for MAGE A3 T Cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular Toxicity and Titin Cross-Reactivity of Affinity-Enhanced T Cells in Myeloma and Melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt Signaling Arrests Effector T Cell Differentiation and Generates CD8 + Memory Stem Cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of Premanufacture CD8+T Cells Determine CAR-T Efficacy in Patients with Diffuse Large B-Cell Lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"doi-asserted-by":"crossref","unstructured":"Ren, H., Cao, K., and Wang, M. (2021). A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy. Front. Immunol., 12.","key":"ref_36","DOI":"10.3389\/fimmu.2021.745109"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-Day Manufacture of a Novel Anti-CD19 CAR-T Therapy for B-Cell Acute Lymphoblastic Leukemia: First-in-Human Clinical Study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:27:55Z","timestamp":1759919275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17020242"],"URL":"https:\/\/doi.org\/10.3390\/cancers17020242","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}